Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination antibiotic therapy consisting of metronidazole (an antibiotic effective against anaerobic bacteria) and piperacillin/tazobactam (a combination of the broad-spectrum penicillin antibiotic piperacillin with the beta-lactamase inhibitor tazobactam). The combination provides coverage against a wide range of bacteria, including aerobic gram-positive, gram-negative, and anaerobic organisms. It's primarily used for treating complicated intra-abdominal infections, though clinical evidence suggests that using piperacillin/tazobactam plus metronidazole (double anaerobic coverage) may be associated with worse outcomes than piperacillin/tazobactam alone in some cases[4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on metronidazole + piperacillin + tazobactam.